Liver involvement Brain involvement Bone marrow Concomitant ET FULV AI TAM/TORE All individuals(n = 211) 53(298) 41(19.four) 170(80.six) 141(67.1) 70(32.9) 73(34.6) 130(61.six) eight(3.8) 50(23.7) 161(76.three) 165(78.two) 46(21.8) 182(86.three) 29(13.7) 94(44.6) 92(43.6) 25(11.8) 69(32.7) 142(67.3) 134(63.five) 77(36.five) 42(19.9) 72(34.1) 78(37.0) 15(7.1) three(1.four) 95(45.0) 112(53.1) 4(1.9) 1st line(n = 85) 55(294) 18(21.two) 67(78.8) 58(69.0) 27(31.0) 29(34.1) 53(62.four) three(3.5) 27(31.8) 58(68.two) 71(83.5) 14(16.five) 70(82.four) 15(17.six) 53(62.4) 28(32.9) 4(4.7) 20(23.five) 65(76.5) 44(51.eight) 41(48.2) 20(23.5) 25(29.4) 24(28.two) 3(3.five) 2(2.4) 35(41.two) 47(55.3) 3(3.five) 2nd line(n = 78) 51(328) 17(21.eight) 61(78.two) 53(67.9) 25(32.1) 30(38.five) 45(57.7) 3(three.eight) 12(15.four) 66(84.6) 57(73.1) 21(26.9) 70(89.7) eight(10.three) 26(33.three) 39(50.0) 13(16.7) 28(35.9) 50(64.1) 52(66.7) 26(33.3) 16(20.five) 27(34.6) 29(37.2) six(7.7) 1(1.three) 43(55.1) 34(43.6) 1(1.3) 3rd line(n = 48) 53(297) six(12.five) 42(87.five) 30(62.five) 18(37.five) 14(29.1) 32(66.7) two(4.two) 11(22.9) 37(77.1) 37(77.1) 11(22.9) 42(87.five) 6(12.5) 15(31.3) 25(52.0) eight(16.7) 21(43.7) 27(56.three) 38(79.2) 10(20.8) 6(12.5) 20(41.7) 25(52.1) 6(12.six) 17(35.four) 31(64.six) -Values are presented as quantity ( ) unless otherwise indicated. ECOG, Eastern Cooperative Oncology Group; ER, Estrogen receptor; PgR, Progesterone receptor; ET, Endocrine therapy; FULV, Fulvestrant; AI, Aromatase Inhibitors; TAM, Tamoxifen; TORE, ToremifeneAt the time of survival data extraction, 106 patients have been nonetheless receiving Palbociclib-based remedy. Soon after a median follow-up period of 14.two months (variety, two.1 to 47.3 months), the median PFS in the overall population was 12.two months (95 CI: ten.14.3 months), and also the median OS was not reached. The median PFS was 14.five months, 10.6 months and eight.7 months in individuals received Palbociclib in first-, second-, and third- or later-line setting, respectively (Fig. 3). More than 3 metastatic web pages (HR: 1.55, 95 CI: 1.02 to 2.35, P = 0.04), with visceral metastasis (HR: 1.91,95 CI: 1.29 to 2.83, P = 0.003), with liver metastasis (HR: 1.81, 95 CI: 1.20 to 2.73, P = 0.003), with brain metastasis (HR: 2.36, 95 CI: 1.11 to five.05, P = 0.026), prior chemotherapy (HR: 1.81, 95 CI: 1.21 to two.70, P = 0.004), and prior ET (HR: 1.61, 95 CI: 1.04 to two.48, P = 0.023) had been connected with a worse PFS, though sufferers with Luminal A variety MBC (HR: 0.52, 95 CI: 0.34 to 0.79, P = 0.002) and with bone metastasis only (HR: 0.61, 95 CI: 0.38 to 0.97, P = 0.038) showed a prolonged PFS (Fig. four).Yang et al. BMC Cancer(2023) 23:Web page six ofTable two Prior therapy for early breast cancer and metastatic breast cancerPrior therapy for EBC Neoadjuvant CHT Surgery Adjuvant CHT Adjuvant RT Adjuvant ET SERM AI Letrozole Anatrozole Exemestane NA Prior therapy for MBC Prior CHT for MBC Prior ET for MBC SERM AI SERD All patients(n = 211) 36(17.Pumecitinib In Vitro 1) 173(82.Y-27632 ROCK 0) 139(65.PMID:23539298 9) 98(46.four) 128(60.7) 66(51.6) 62(48.4) 35(27.three) five(3.9) 13(ten.2) 9(7.0) 82(38.9) 63(29.9) four(6.three) 22(34.9) 37(58.7) 1st line(n = 85) 17(20.0) 62(72.9) 51(60) 37(43.five) 45(52.9) 22(47.8) 24(52.2) 13(28.three) 2(4.3) four(eight.7) 5(10.9) 7(eight.2) 2nd line(n = 78) 14(17.9) 69(88.5) 49(62.8) 35(44.9) 48(62.8) 25(52.1) 23(47.9) 10(20.eight) 1(2.2) 8(16.7) 4(eight.7) 38(48.7) 30(38.5) three(10.0) 12(40.0) 15(50.0) 3rd line(n = 48) 5(10.4) 42(87.5) 39(81.three) 26(54.two) 34(70.eight) 19(55.9) 15(44.1) 12(35.two) 2(5.9) 1(2.9) 37(77.1) 33(68.eight) 1(three.0) 10(30.3) 22(66.7)Values are presented as number ( ) unless otherwise indicated. EBC, Early breast cancer; CHT, Chemotherapy; RT,.